Detalles de la búsqueda
1.
Effect of switching from natalizumab to moderate- vs high-efficacy DMT in clinical practice.
Neurol Clin Pract
; 10(6): e53-e65, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-33510948
2.
Effect of tobacco use on disease activity and DMT discontinuation in multiple sclerosis patients treated with dimethyl fumarate or fingolimod.
Mult Scler J Exp Transl Clin
; 6(4): 2055217320959815, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33110616
3.
Disease activity outcomes with different washout periods after switching from natalizumab to an alternative disease-modifying therapy.
J Neurol
; 267(8): 2214-2220, 2020 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-32270292
4.
Duration of natalizumab therapy and reasons for discontinuation in a multiple sclerosis population.
Mult Scler J Exp Transl Clin
; 6(1): 2055217320902488, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32064117
5.
Changes in patient-reported outcomes between continuers and discontinuers of disease modifying therapy in patients with multiple sclerosis over age 60.
Mult Scler Relat Disord
; 30: 252-256, 2019 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-30851638
6.
Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up.
J Neurol Sci
; 407: 116498, 2019 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31644992
7.
Corrigendum to "Changes in patient-reported outcomes between continuers and discontinuers of disease modifying therapy in patients with multiple sclerosis over age 60" [Multiple Sclerosis and Related Disorders 30 (2019) 252-256].
Mult Scler Relat Disord
; 30: 293, 2019 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-30987754
Resultados
1 -
7
de 7
1
Próxima >
>>